Cardinal Health partners with NRx for distribution of Covid therapy

NRx Pharmaceuticals, a clinical-stage pharma company, has signed an agreement with pharma distribution heavyweight Cardinal Health to provide third-party logistics (3PL) and exclusive distribution of ZYESAMI (branded form of aviptadil), as it awaits the possible emergency use authorization (EUA) approval by the FDA. In May, NRx submitted the EUA application for patients suffering from critical Covid-19 with respiratory failure.

Cardinal Health's 3PL services will support the warehousing and distribution, full order to cash, and necessary title model services.

"This partnership creates an efficient and highly flexible logistics and distribution model for NRx. Cardinal Health's expertise will enable ZYESAMI to quickly reach patients in the intensive care units, as limiting the time to treatment is crucial," says Robert Besthof, NRx’s head of operations and chief commercial officer. "This also allows NRx to continue focusing on answering requests from the FDA in support of our application for emergency use authorization for ZYESAMI."

The drug has been granted fast-track designation by FDA. It's currently undergoing Phase III clinical trials, and recruiting. Participants will either inhale ZYESAMI by mesh nebulizer, or placebo.